Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Protara Therapeutics stock

Own Protara Therapeutics stock in just a few minutes.

Protara Therapeutics, Inc is a biotechnology business based in the US. Protara Therapeutics shares (TARA) are listed on the NASDAQ and all prices are listed in US Dollars. Protara Therapeutics employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Protara Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TARA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Protara Therapeutics share price

Use our graph to track the performance of TARA stocks over time.

Protara Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$12.04 - $67.08
50-day moving average $15.73
200-day moving average $19.62
Wall St. target price$45.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-30.61

Buy Protara Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Protara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protara Therapeutics financials

Gross profit TTM $0
Return on assets TTM -21.07%
Return on equity TTM -34.48%
Profit margin 0%
Book value N/A
Market capitalisation $136.8 million

TTM: trailing 12 months

Shorting Protara Therapeutics shares

There are currently 288,871 Protara Therapeutics shares held short by investors – that's known as Protara Therapeutics's "short interest". This figure is 38.7% up from 208,200 last month.

There are a few different ways that this level of interest in shorting Protara Therapeutics shares can be evaluated.

Protara Therapeutics's "short interest ratio" (SIR)

Protara Therapeutics's "short interest ratio" (SIR) is the quantity of Protara Therapeutics shares currently shorted divided by the average quantity of Protara Therapeutics shares traded daily (recently around 105813.55311355). Protara Therapeutics's SIR currently stands at 2.73. In other words for every 100,000 Protara Therapeutics shares traded daily on the market, roughly 2730 shares are currently held short.

However Protara Therapeutics's short interest can also be evaluated against the total number of Protara Therapeutics shares, or, against the total number of tradable Protara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protara Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Protara Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0387% of the tradable shares (for every 100,000 tradable Protara Therapeutics shares, roughly 39 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Protara Therapeutics.

Find out more about how you can short Protara Therapeutics stock.

Protara Therapeutics share dividends

We're not expecting Protara Therapeutics to pay a dividend over the next 12 months.

Have Protara Therapeutics's shares ever split?

Protara Therapeutics's shares were split on a 1:40 basis on 9 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protara Therapeutics shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Protara Therapeutics shares which in turn could have impacted Protara Therapeutics's share price.

Protara Therapeutics overview

Protara Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site